Herman F. Staats

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.

Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection.

Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.

Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus.

Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines.

Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.

Oral immunogenicity of the plant proteinase bromelain.

Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics.

In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Mast cell activators: a new class of highly effective vaccine adjuvants.

An entirely cell-based system to generate single-chain antibodies against cell surface receptors.

Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.

Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage library.

The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

Mast cell-derived particles deliver peripheral signals to remote lymph nodes.

Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues.

Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.

Adenovirus F protein as a delivery vehicle for botulinum B.

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Cytokines: the future of intranasal vaccine adjuvants.

Stable dry powder formulation for nasal delivery of anthrax vaccine.

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Evaluation of vaccine-induced antibody responses: impact of new technologies.

Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.

A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents.

A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.

Salmonella typhimurium impedes innate immunity with a mast-cell-suppressing protein tyrosine phosphatase, SptP.

Which comes first: the antigen or the adjuvant?

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.

Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.

Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface.

Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Assessing the satisfaction and burden within an academic animal care and use program.

Effect of endotoxin and alum adjuvant vaccine on peanut allergy.

Vaccine adjuvants: Softness makes it better.

Mast cell activators as novel immune regulators.

Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles.

Nasal peanut+ CpG immunotherapy enhances peanut-specific IFN-γ in Th2 cells and IL-10 in non-Th2 cells in mice.

Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening.

Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Softness makes it better.

Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.

Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.